drugset / Trial / NCT05981963

A Study to Evaluate the Drug Levels, Physical and Chemical Changes, and Removal of BMS-986196 in Healthy Male Participants

NCT05981963

Phase 1 Completed 8 enrolled Bristol-Myers Squibb
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the excretion pathway of orally administered \[14C\]-BMS-986196 and to assess the safety and tolerability of orally administered BMS-986196.

Timeline

Start
2023-08-17
Primary completion
2023-10-22
Completion
2023-10-22

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986196 Unknown 60 mg Oral

Indications

No indication recorded.